Literature DB >> 2004358

Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers.

J M Ford1, W N Hait, S A Matlin, C C Benz.   

Abstract

Several cell lines resistant to alkylating agents possess increased activity of glutathione-S-transferase (GST) drug detoxifying enzymes. Inhibition of certain enzymes of the glutathione redox system may affect cellular sensitivity to alkylators. We report that the (-.)enantiomer of gossypol is a potent and selective inhibitor of GST alpha and GST pi isozymes, and that in combination with buthionine sulfoximine (BSO), causes the enhanced modulation of alkylator resistance in two drug resistant cell lines with increased GST activity. The use of (-)gossypol alone had no effect on the 2-5-fold resistance of MCF-7 Adr and Walker resistant cells to chlorambucil, melphalan and BCNU. Cellular depletion of glutathione with BSO resulted in a 2-4-fold modulation of cell sensitivity to these alkylators. However, the combination of (-)gossypol with BSO resulted in a markedly greater modulation of alkylator sensitivity than with either inhibitor alone. Therefore, the complementary inhibition of glutathione and GST by BSO and (-)gossypol, respectively, produced a synergistic modulation of alkylator cytotoxicity in these drug resistant cell lines. The favorable clinical pharmacokinetics of (-)gossypol suggest its further evaluation for use in combination with BSO and alkylating agents in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004358     DOI: 10.1016/0304-3835(91)90198-q

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  Gossypol treatment of recurrent adult malignant gliomas.

Authors:  P Bushunow; M M Reidenberg; J Wasenko; J Winfield; B Lorenzo; S Lemke; B Himpler; R Corona; T Coyle
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

2.  Developing gossypol derivatives with enhanced antitumor activity.

Authors:  X S Liang; A J Rogers; C L Webber; T J Ormsby; M E Tiritan; S A Matlin; C C Benz
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 3.  Small-molecule inhibitors reveal a new function for Bcl-2 as a proangiogenic signaling molecule.

Authors:  Benjamin D Zeitlin; Jacques E Nör
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

4.  Sex-dependent expression and growth hormone regulation of class alpha and class mu glutathione S-transferase mRNAs in adult rat liver.

Authors:  P K Srivastava; D J Waxman
Journal:  Biochem J       Date:  1993-08-15       Impact factor: 3.857

Review 5.  The role of glutathione-S-transferase in anti-cancer drug resistance.

Authors:  Danyelle M Townsend; Kenneth D Tew
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

6.  Isozyme specificity of novel glutathione-S-transferase inhibitors.

Authors:  J E Flatgaard; K E Bauer; L M Kauvar
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.

Authors:  Benjamin D Zeitlin; Isaac J Zeitlin; Jacques E Nör
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

8.  Characterization of nanoparticles combining polyamine detection with photodynamic therapy.

Authors:  Wenting Li; Lingyun Wang; Tianlei Sun; Hao Tang; Brian Bui; Derong Cao; Ruibing Wang; Wei Chen
Journal:  Commun Biol       Date:  2021-07-01

Review 9.  Cancer drugs, genetic variation and the glutathione-S-transferase gene family.

Authors:  Danyelle Townsend; Kenneth Tew
Journal:  Am J Pharmacogenomics       Date:  2003

10.  Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy.

Authors:  A G van der Zee; B van Ommen; C Meijer; H Hollema; P J van Bladeren; E G de Vries
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.